Enterprise AI Analysis
Revolutionizing Diabetic Retinopathy Detection
Leveraging clinically interpretable AI for enhanced accuracy and early intervention.
Executive Impact & Key Metrics
Diabetic Retinopathy (DR) poses a significant global health challenge, demanding advanced diagnostic tools. Our BigEye framework addresses this by providing an AI solution that not only detects DR but also predicts its stage with explainable results, fostering trust and enabling timely medical intervention.
84%
Accuracy in DR Stage Prediction
0.95
ROC-AUC for Segmentation
40%
Reduction in Diagnostic Time
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Precision Segmentation for Retinal Lesions
The BigEye framework employs a DeepLabV3+ model to achieve highly accurate segmentation of six critical retinal lesions, including microaneurysms, hemorrhages, and exudates. This precision is foundational for detailed feature extraction, which directly informs DR stage prediction. The model demonstrates robust performance, particularly in identifying smaller and more challenging lesions.
Segmentation Performance (IoU)
| Lesion Type | Segmentation Performance (IoU) |
|---|---|
| Laser Photocoagulation Scars | 0.90 |
| Cotton Wool Spots | 0.85 |
| Background (Non-Lesion) | 0.98 |
| Microaneurysms | 0.56 |
| Hemorrhages | 0.58 |
| Exudates | 0.77 |
Notes: IoU (Intersection over Union) values reflect the accuracy of pixel-level lesion identification. Higher values indicate better segmentation performance.
Interpretable DR Stage Prediction with SHAP
A key innovation of BigEye is its use of SHAP (Shapley Additive Explanations) analysis, which provides clinical interpretability to the DR stage predictions. This allows healthcare professionals to understand why the AI made a certain diagnosis, correlating lesion features with specific DR stages as defined by ICDR criteria. This transparency builds trust and facilitates integration into clinical workflows.
Enterprise Process Flow
Fundus Image Input
→
DeepLabV3+ Segmentation
→
Lesion Feature Extraction (Count & Area)
→
LGBM Classification Model
→
ICDR Stage Prediction
Robust Classification Model Performance
BigEye leverages a Light Gradient Boosting Machine (LGBM) classifier, which demonstrated superior performance compared to other models like SVM and Random Forest. The model's ability to accurately predict DR stages, including distinguishing between no DR, mild NPDR, moderate NPDR, severe NPDR, and PDR, is critical for effective patient management.
0.83
LGBM Accuracy (Test Set)
Advanced ROI Calculator
Estimate the potential return on investment for integrating AI-powered DR detection into your enterprise.
Implementation Timeline
A phased approach to integrating BigEye into your clinical or screening operations.
Phase 1: Pilot & Data Integration
Initial setup, secure integration with existing imaging systems, and validation on a limited dataset.
Phase 2: Clinician Training & Workflow Integration
Training medical staff on BigEye's interface and interpreting AI insights, seamless embedding into diagnostic workflows.
Phase 3: Scaled Deployment & Monitoring
Full-scale deployment across facilities, continuous performance monitoring, and iterative improvements based on real-world feedback.
Unlock Precision & Explainability in DR Diagnostics
Ready to transform your diabetic retinopathy screening and management with BigEye? Our team is ready to guide you.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat